Abstract:Abstract Background and objective Both nateglinide and acarbose can decrease postprandial plasma glucose through different mode of action, therefore may improve oxidative stress and inflammation in patients with type 2 diabetes mellitus (T2DM). There is lack of comprehensive data on effects of nateglinide versus acarbose on plasma glucose level, lipid profiles and inflammatory response of postprandial status in drug naïve Chinese patients with T2DM, therefore we conducted a clinical trial to answer these questions. Methods In a 4-week, randomized, active-control, open-label, parallel-group, multicenter trial, 160 anti-diabetic drug-naïve T2DM patients were randomized to receive either nateglinide or acarbose for 4 weeks. Postprandial glucose profiles with postprandial glucose excursion (PPGE), postprandial lipids profile and the postprandial pro-inflammatory factor of high sensitivity C - reactive protein (hsCRP) were assessed in a standardized meal test. Results Both nateglinide and acarbose could reduce PPGE 2 h significantly (P<0.01) and the two drugs had comparable effects on reducing glycated albumin (-1.2+1.57% and -1.2+2.13%, P<0.01). Nateglinide markedly decreased free fatty acids (FFA) at postprandial 30, 60, 90 minute (P<0.05), however acarbose had no effect on FFA. Furthermore, acarbose decreased fasting HDL-C significantly (P<0.01). No significant effect on hsCRP was found in either group. The number of people experiencing adverse events was similar (nateglinide 13.8%, acarbose 18.8%, P=0.521) and there was low frequency of symptomatic hypoglycemia in both groups (nateglinide 5%, acarbose 1.3%). No confirmed hypoglycemia or serious hypoglycemia was observed. Several limitations in the present study include that we cannot exclude the effect of behavior change in the glycemic control through the study, and the number of subjects was relatively small. Conclusions Nateglinide and acarbose were similar in controlling the postprandial glucose in Chinese drug naïve patients with T2DM. In addition, nateglinide had better performance on improving lipids metabolism under postprandial status in comparison with acarbose. Overall, nateglinide had a safety profile similar to acarbose in this study.

Acarbose Unveiled: A Breakthrough in Postprandial Hypotension Treatment

Effectiveness of acarbose in treating elderly patients with diabetes with postprandial hypotension.

Nateglinide and Acarbose Are Comparably Effective Reducers of Postprandial Glycemic Excursions in Chinese Antihyperglycemic Agent-Naive Subjects with Type 2 Diabetes

Acarbose is again on the stage

Improved post-prandial ghrelin response by nateglinide or acarbose therapy contributes to glucose stability in Type 2 diabetic patients

Differential Therapeutic Effects of Nateglinide and Acarbose on Fasting and Postprandial Lipid Profiles: a Randomized Trial.

Evaluation of Acarbose Bioequivalence in Healthy Chinese Populations Using Novel Pharmacodynamic End Points

Acarbose treatment of sulfonylurea-treated non-insulin dependent diabetics. A double-blind cross-over comparison of an alpha-glucosidase inhibitor with metformin.

Intervention Effect of Acarbose on Metabolic Syndrome

Canagliflozin or acarbose versus placebo to ameliorate post‐bariatric hypoglycaemia – The HypoBar I randomized clinical trial protocol

Rationale for and Design of the Acarbose Cardiovascular Evaluation (ACE) Trial.

Acarbose Reduces Body Weight Irrespective of Glycemic Control in Patients with Diabetes: Results of a Worldwide, Non-Interventional, Observational Study Data Pool

Combination therapy of bioactive compounds with acarbose: A proposal to control hyperglycemia in type 2 diabetes

Effects of 24-Week Treatment with Acarbose on Glucagon-Like Peptide 1 in Newly Diagnosed Type 2 Diabetic Patients: a Preliminary Report

Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review

Therapeutic potential of acarbose in ameliorating the metabolic and endocrinological complications of polycystic ovarian syndrome: a review

The alpha-glucosidase inhibitor acarbose reduces the net electronegative charge of low-density lipoprotein in patients with newly diagnosed type 2 diabetes

Efficacy and Safety of Acarbose Chewable Tablet in Patients with Type 2 Diabetes: a Multicentre, Randomized, Double-Blinded, Double-Dummy Positive Controlled Trial.

Efficacy of acarbose in Chinese subjects with impaired glucose tolerance.

Effects of Acarbose on the Gut Microbiota of Prediabetic Patients: A Randomized, Double-blind, Controlled Crossover Trial

Effects of Nateglinide on Postprandial Plasma Glucose Excursion and Metabolism of Lipids in Chinese Patients with Type 2 Diabetes：A 4-Week, Randomized, Active-Control, Open-Label, Parallel-Group, Multicenter Trial.